Needle Biopsy Market

According to a new report published by Introspective Market Research, titled, “Needle Biopsy Market by Needle Type, Application, and End-User: Global Opportunity Analysis and Industry Forecast, 2024–2032,” 

the global Needle Biopsy Market Size Was Valued at USD 1.2 Billion in 2023, and is Projected to Reach USD 2.13 Billion by 2032, Growing at a CAGR of 6.60% From 2024-2032.

A needle biopsy involves extracting tissue samples through a thin, sharp-tipped tube guided by imaging techniques like ultrasound or MRI. This non-surgical procedure is crucial for diagnosing infections, inflammation, or cancerous cells in organs such as the breast, liver, lung, and bone. Its resurgence is fueled by rising chronic diseases, advanced imaging methods, and less invasive diagnostic trends. Fine needle aspiration and core needle biopsy are preferred for their accuracy, safety, and cost-effectiveness over traditional surgical biopsies. Technological advancements, including imaging and robotic assistance, enhance biopsy precision, making it popular globally. Increasing disease awareness and an aging population contribute to its growing demand. Market segmentation includes software/services, applications in oncology, pulmonology, and urology, and regional divisions like Americas, APAC, Europe, and others. Major players focus on product innovation, partnerships, and acquisitions to expand market presence and foster competition and innovation.  

According to the global Needle Biopsy market analysis, the market is divided by needle Type, Application, End-User, and geographical division. By Needle Type, the market is categorized into Trephine Biopsy Needles, Klima Sternal Needles, Salah Needle Aspiration Needles, Jamshidi Needles, and Others. By Application, the market is categorized into Tumour/Cancer, Breast, Lung, Prostate, Colon, Stomach, Liver Cervix uterus, Thyroid, Infection, Inflammation, and Others. By End User, the market is categorized into Hospitals, Diagnostic Centres, Biopsy Labs, Ambulatory Surgical Centres, Academic and Research Organizations, and Others. By geography, it includes North America, Europe, Asia-Pacific, and LAMEA markets. Further, the report also covers the strategies adopted by key market players to sustain a competitive environment and increase their market share.

The increasing adoption of liquid biopsy techniques represents a significant trend in the diagnostic landscape, offering less invasive methods compared to traditional tissue biopsies. Utilizing blood samples, liquid biopsies provide genetic and molecular insights into diseases like cancer, aiding in early detection and personalized treatment strategies. Advancements in technologies such as next-generation sequencing (NGS) and molecular diagnostics enhance the specificity and effectiveness of liquid biopsies, making them increasingly favored in clinical practice.

Concurrently, the integration of artificial intelligence (AI) and machine learning (ML) is transforming the needle biopsy market by improving diagnostic precision and efficiency. AI and ML enable automated analysis of biopsy samples, enhance imaging accuracy, and interpret vast datasets, potentially reducing human errors and identifying subtle disease patterns early on, including cancer. This technological synergy is particularly promising in regions with limited access to specialized medical professionals, augmenting local healthcare capabilities. Collaboration among technology firms, healthcare providers, and academia is pivotal in advancing AI-assisted needle biopsy techniques, promising better patient outcomes through more tailored and specific diagnostics.

Global Needle Biopsy Market, Segmentation

The Needle Biopsy market is segmented based on needle type, application, end-user, and region.

Needle Type:

The market within which Trephine Biopsy Needles is likely to have the leading market share is the Needle Biopsy Market during the upcoming years. Trephine biopsy needles are usually large enough to take a more extensive core biopsy of the bone or soft tissue and therefore allow for enhanced histological evaluation. This makes them useful, especially in cases where the disease is extensive for instance bone marrow ailments, cancers, and other diseases that need large tissue samples for proper assessment. It has been noted that these diseases are on the rise and patients need accurate diagnostic tools, which are encouraging the use of trephine biopsy needles. In addition, the same for improved technology and materials utilized in needle manufacturing has increased their safety and effectiveness and therefore the comfort of the patient propelling their use by health care practitioners. Consequently, the consumption and growth rate of the trephine biopsy needles segment has boosted the segment’s leading position in the global needle biopsy market consistently.

Application:

The rising incidence of cancer globally continues to drive growth in the tumor/cancer segment market. Needle biopsies, including Fine Needle Aspiration and Core Needle Biopsies, play a crucial role in diagnosing and staging cancer by obtaining tissue samples for histopathological examination. The shift towards early detection and targeted therapies underscores the demand for sensitive and minimally invasive diagnostic methods. Innovations in imaging techniques and biopsy needles have enhanced safety and efficacy, making them preferred among oncologists. Increased awareness and healthcare sector advancements, particularly in emerging regions, further contribute to the dominance of needle biopsies in the global market for cancer diagnosis and treatment.

Region:

The Asia Pacific needle biopsy market is poised for substantial growth, driven by several factors. Increasing healthcare expenditures in the region support the adoption of advanced diagnostic methods such as needle biopsies. Rising incidences of cancers and chronic diseases, particularly in densely populated countries like China and India, emphasize the need for minimally invasive sampling techniques. Government initiatives promoting early disease detection, coupled with growing awareness among healthcare providers and patients, further bolster market expansion. Additionally, foreign investments and collaborations with international medical device manufacturers are enhancing product quality and technological advancements in biopsy technologies.

Some of The Leading/Active Market Players Are-

• AMECATH (Egypt)
• AprioMed AB (Sweden)
• Argon Medical Devices (U.S.)
• B. Braun SE (Germany)
• BD (U.S.)
• Boston Scientific Corporation (U.S.)
• Cardinal Health (U.S.)
• Cook Group (U.S.)
• HAKKO CO., LTD. (Japan)
• Hologic, Inc. (U.S.), and Other Active Players

Key Industry Developments

• In May 2024, Hologic launched its Brevera Breast Biopsy System 7-gauge needle in Europe, expanding its range of disposable biopsy options. This addition enhances biopsy procedures by offering radiologists more flexibility and potentially reducing patient discomfort and compression time.
• In June 2023, Argon Medical launched the SuperCore Advantage, a new semi-automatic biopsy instrument in the USA. This disposable device enhances tissue sample volume, aiding accurate diagnoses crucial for patient care. Available in various sizes, it meets diverse clinical needs. George Leondis, CEO of Argon Medical, emphasized its development in collaboration with healthcare professionals to improve biopsy precision and patient outcomes.

Key Findings of the Study 

• The global needle biopsy market is expected to grow from USD 1.2 billion in 2023 to USD 2.13 billion by 2032, at a CAGR of 6.60% from 2024-2032, driven by advancements in imaging techniques and increasing demand for less invasive diagnostic procedures.
• Integration of AI and machine learning is enhancing diagnostic precision and efficiency in needle biopsies, offering automated analysis of biopsy samples and improving imaging accuracy.